BARD1 Life Sciences Ltd is an Australia-based life sciences company. The Company is engaged in developing diagnostics and therapeutics for unmet needs in cancer. Its proprietary BARD1 Technology is based on BARD1, a potent tumour suppressor in healthy individuals and important tumour biomarker in cancer. Its lead product the BARD1 Lung Cancer Test is a non-invasive blood test in development for early detection of lung cancer. It is also engaged in researching a pipeline of potential diagnostic and therapeutic products for multiple cancers. The Company’s pipeline also includes BARD1 Ovarian Cancer Test and BARD1 Ribonucleic Acid (RNA) Test.